Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0814 OSI
OSI & Getty Images

Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

OSI parlays University of Oxford deal into $800M evergreen fund, expanding portfolio

OSI has parlayed its long-term deal with University of Oxford into an $800 million evergreen fund and an expanding life sciences portfolio.

Aug 14, 2020 | 9:34 PM GMT

A long-term agreement with the University of Oxford has provided a strong foundation on which investment firm Oxford Sciences Innovation has been able to build its fund-raising and broaden its portfolio into new disease areas and modalities.

Despite Oxford’s more than 800-year history, its arrangement with Oxford Sciences Innovation (OSI) may be its first successful attempt at systematically driving the translation and commercialization of its IP through company creation.

OSI was founded in 2015 as an independent evergreen investment firm on the

Read the full 1352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE